Once‐weekly subcutaneous semaglutide treatment for persons with type 2 diabetes: Real‐world data from a diabetes out‐patient clinic

Jul 22, 2021Diabetic medicine : a journal of the British Diabetic Association

Weekly semaglutide injections for people with type 2 diabetes: Real-world clinic results

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

After 12 months, HbA1c levels decreased by 12.8 mmol/mol in GLP-1RA naïve individuals and by 6.4 mmol/mol in those with prior GLP-1RA experience.

Significant reductions in HbA1c levels were observed in both GLP-1RA naïve (-12.8 mmol/mol) and experienced (-6.4 mmol/mol) participants.
Body weight decreased by an average of 5 kg in GLP-1RA naïve individuals and 3.2 kg in those with previous GLP-1RA treatment.
The majority of participants (75%) received 1 mg of semaglutide once weekly.
Results align with outcomes reported in clinical trials, suggesting similar effectiveness in real-world settings.

AI simplified

AIMS: The once-weekly administered glucagon-like peptide 1 (GLP-1) receptor agonist (GLP-1RA) semaglutide, has, in clinical trials, demonstrated significant reductions in glycated haemoglobin A(HbA) and body weight in persons with type 2 diabetes. We evaluated the real-world clinical effects of semaglutide once weekly in a hospital-based diabetes out-patient clinic. 1c1c

METHODS: This retrospective observational cohort study included persons with type 2 diabetes (n = 119) on a broad range of antidiabetic medicine: GLP-1RA naïve persons (n = 37) and GLP-1RA-experienced persons (n = 82). Person characteristics at inclusion: age [median (quartiles)]: 65 (57, 72) years; body weight 99 (86, 118) kg; body mass index (BMI) 33 (29, 38) kg/m²; HbA61 (54, 69) mmol/mol/(7.7 (7.1, 8.5) %). Data were collected at baseline and after 3, 6 and 12 months of semaglutide treatment. Data were analysed using a general linear mixed model for repeated measurements. 1c

RESULTS: After 12 months, the reductions in HbAwere (mean [95% confidence interval]: GLP-1RA naïve: -12.8 [-17.0, -8.5] mmol/mol/ -1.2 [-1.6, -0.8]% (p < 0.01) and GLP-1RA experienced: -6.4 [-9.0, -3.8] mmol/mol/ -0.6 [-0.8, -0.4]% (p < 0.01), respectively. Body weight reductions in GLP-1RA naïve: -5 [-6.9, -3.1] kg (p < 0.01) and GLP-1RA experienced: -3.2 [-4.4, -2.0] kg (p < 0.01), respectively. Seventy-five percent received 1 mg QW semaglutide. 1c

CONCLUSION: We observed effects of semaglutide once weekly on HbAand body weight comparable with the effects observed in clinical studies with fewer persons in our cohort receiving maximum dose of semaglutide. 1c

Full Text

Full text is available at the source.

View full text (PDF) ↗View full text (XML) ↗View full text ↗

Once‐weekly subcutaneous semaglutide treatment for persons with type 2 diabetes: Real‐world data from a diabetes out‐patient clinic

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief